As discussed, there is now compelling preclinical evidence denoting the potential of targeting AXL to mediate sensitization of cancer cells to immune cell-mediated attack and diminish immunosuppression within the TIME, with beneficial additive or synergistic effects in combination with ICI. This evidence concerns the gene AXL and cancer.